Formulation of an erodible, gastric retentive oral diuretic

• US 20030152622A1
• Filed: 11/12/2002
• Published: 08/14/2003
• Est. Priority Date: 10/25/2001
• Status: Abandoned Application

• Current Assignee: Assertio Therapeutics, Inc. (Assertio Holdings, Inc.)
• Original Assignee: Assertio Therapeutics, Inc. (Assertio Holdings, Inc.)
• Inventors: Berner, Bret, Louie-Helm, Jenny, Urquhart, John
• Application Number:
  US10/293,217
• Publication Number:
  US 20030152622A1
• Time in Patent Office: Days
• US Class Current: 424/468
• CPC Class Codes: A61K 31/35 having six-membered rings with one oxygen as the only ring hetero atom
• CPC Class Codes: A61K 31/351 not condensed with another ring
• CPC Class Codes: A61K 31/635 having a heterocyclic ring, e.g. sulfadiazine
• CPC Class Codes: A61K 33/00 Medicinal preparations containing inorganic active ingredients
• CPC Class Codes: A61K 49/0404 containing barium sulfate
• CPC Class Codes: A61K 9/0065 Forms with gastric retention, e.g. floating on gastric juice, adhering to gastric mucosa, expanding to prevent passage through the pylorus
• CPC Class Codes: A61K 9/2027 obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
• CPC Class Codes: A61K 9/2031 obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
• CPC Class Codes: A61K 9/2054 Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
• CPC Class Codes: A61K 9/5031 obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poly(lactide-co-glycolide)

Abstract

An erodible, gastric-retentive oral diuretic is provided that is formulated using the in vitro drug release profile obtained with USP Disintegration test equipment rather the USP Dissolution Apparatus. The invention is premised on the discovery that the USP Disintegration Test and modified versions thereof are far more predictive of the in vivo release profile for a controlled release dosage form than is the standard USP Dissolution Test, particularly controlled release dosage forms of the swellable, erodible type. The dosage forms generally comprise particles of a biocompatible, hydrophilic polymer having the active agent incorporated therein, wherein the particles are optionally but preferably compacted into a tablet or loaded into a capsule. The dosage forms can be used to deliver water-insoluble or sparingly soluble drugs as well as water-soluble drugs, providing that the latter are coated with a protective coating or contained in a protective vesicle. Using the controlled release dosage form, adverse side effects associated with peak diuresis are diminished or eliminated, while the overall diuretic effect of the drug is maintained.

Claims

1. An erodible, gastric-retentive drug dosage form for delivering a pharmacologically active agent to the stomach, duodenum, and upper small intestine of a patient, the dosage form comprising the pharmacologically active agent incorporated in a matrix of at least one biocompatible, hydrophilic polymer that (a) swells in the presence of water in gastric fluid such that the size of the dosage form is sufficiently increased to provide gastric retention in the stomach of a patient in whom the fed mode has been induced, (b) gradually erodes within the gastrointestinal tract over a determinable time period, and (c) releases the active agent throughout the determinable time period, wherein the dosage form is formulated so as to provide an active agent release profile in vivo that corresponds to a desired active agent release profile obtained for the dosage form in vitro using USP disintegration test equipment;

wherein the active agent is a diuretic agent.

2. The dosage form of claim 1, wherein a first fraction of the active agent is released from the dosage form by diffusing out of the polymer matrix as a result of (a) and a second fraction of the active agent is released from the dosage form by erosion of the polymer matrix during (b).

3. The dosage form of claim 2, wherein the second fraction is greater than the first fraction.

4. The dosage form of claim 3, wherein at least 75 wt. % of the active agent is released within the determinable time period.

5. The dosage form of claim 4, wherein at least 85 wt. % of the active agent is released within the determinable time period.

6. The dosage form of claim 1, wherein the at least one biocompatible hydrophilic polymer is selected from the group consisting of:

polyalkylene oxides;

cellulosic polymers;

acrylic acid and methacrylic acid polymers, and esters thereof;

maleic anhydride polymers;

polymaleic acid;

poly(acrylamides);

poly(olefinic alcohol)s;

poly(N-vinyl lactams);

polyols;

polyoxyethylated saccharides;

polyoxazolines;

polyvinylamines;

polyvinylacetates;

polyimines;

starch and starch-based polymers;

polyurethane hydrogels;

chitosan;

polysaccharide gums;

zein;

shellac-based polymers; and

copolymers and mixtures thereof.

7. The dosage form of claim 6, wherein the at least one biocompatible hydrophilic polymer is a polyalkylene oxide polymer or copolymer, a cellulosic polymer, a gum, or a mixture thereof.

8. The dosage form of claim 7, wherein the at least one biocompatible hydrophilic polymer is a polyalkylene oxide selected from the group consisting of poly(ethylene oxide), poly(ethylene oxide-co-propylene oxide), and mixtures thereof.

9. The dosage form of claim 8, wherein the at least one biocompatible hydrophilic polymer is poly(ethylene oxide) optionally in admixture with poly(ethylene oxide-co-propylene oxide).

10. The dosage form of claim 6, wherein the at least one biocompatible hydrophilic polymer is a cellulosic polymer selected from the group consisting of hydroxymethylcellulose, hydroxyethylcellulose, hydroxypropylcellulose, hydroxypropyl methylcellulose, carboxymethylcellulose, and mixtures thereof.

11. The dosage form of claim 6, wherein the at least one biocompatible hydrophilic polymer is xanthan gum.

12. The dosage form of claim 1, wherein the at least one biocompatible hydrophilic polymer has a number average molecular weight in the range of approximately 5,000 and 20,000,000.

13. The dosage form of claim 1, wherein the weight ratio of the active agent to the biocompatible hydrophilic polymer is in the range of about 1:

500 to about 85;

15.

14. The dosage form of claim 13, wherein the weight ratio of the active agent to the biocompatible hydrophilic polymer is in the range of about 5:

95 to about 80;

20.

15. The dosage form of claim 14, wherein the weight ratio of the active agent to the biocompatible hydrophilic polymer is in the range of about 30:

70 to about 80;

20.

16. The dosage form of claim 15, wherein the weight ratio of the active agent to the biocompatible hydrophilic polymer is in the range of about 30:

70 to about 70;

30.

17. The dosage form of claim 1, wherein at least one of the biocompatible hydrophilic polymers is crosslinked.

18. The dosage form of claim 1, wherein the active agent has an aqueous solubility of less than about 25 wt. % at 20°

C.

19. The dosage form of claim 18, wherein the active agent has an aqueous solubility of less than about 10 wt. % at 20°

C.

20. The dosage form of claim 19, wherein the active agent has an aqueous solubility of less than about 5 wt. % at 20°

C.

21. The dosage form of claim 1, wherein the active agent has a molecular weight greater than 300 daltons.

22. The dosage form of claim 18, wherein the at least one biocompatible hydrophilic polymer has a number average molecular weight in the range of about 10,000 to 8,000,000.

23. The dosage form of claim 1, wherein the diuretic agent is selected from the group consisting of azetazolamide, amiloride, azosemide, bendroflumethiazide, bumetamide, chlorothiazide, chlorthalidone, ethacrynic acid, furosemide, hydrochlorothiazide, metolazone, muzolimine, nesiritide, piretamide, spironolactone, torsemide, triamterine, and tripamide.

24. The dosage form of claim 23, wherein the diuretic agent is furosemide.

25. The dosage form of claim 1, further comprising an antihypertensive agent.

26. The dosage form of claim 25, wherein the antihypertensive agent is selected from the group consisting of amlodipine, benazepril, darodipine, diltiazem, doxazosin, enalapril, eposartan, esmolol, felodipine, fenoldopam, fosinopril, guanabenz, guanadrel, guanethidine, guanfacine, hydralazine, losartan, metyrosine, minoxidil, nicardipine, nifedipine, nisoldipine, phenoxybenzamine, prazosin, quinapril, reserpine, terazosin, and valsartan.

27. The dosage form of claim 1, further comprising an angiotensin converting enzyme (ACE) inhibitor.

28. The dosage form of claim 27, wherein the ACE inhibitor is selected from the group consisting of enalapril, 1-carboxymethyl-3-1-carboxy-3-phenyl-(1S)-propylamino-2,3,4,5-tetrahydro-1H-(3S)-1-benzazepine-2-one, 3-(5-amino-1-carboxy-1S-pentyl)amino-2,3,4,5-tetrahydro-2-oxo-3S-1H-1-benzazepine-1-acetic acid or 3-(1-ethoxycarbonyl-3-phenyl-(1S)-propylamino)-2,3,4,5-tetrahydro-2-oxo-(3S)-benzazepine-1-acetic acid monohydrochloride.

29. The dosage form of claim 1, further comprising an angiotensin II receptor blocking agent.

30. The dosage form of claim 29, wherein the angiotensin II receptor blocking agent is selected from the group losartan, irbesartan, candesartan, telmisartan, eposartan, and valsartan.

31. The dosage form of claim 1, wherein the active agent is contained within a vesicle.

32. The dosage form of claim 31, wherein the active agent is water soluble but rendered sparingly water soluble by the vesicle.

33. The dosage form of claim 32, wherein the vesicle is selected from the group consisting of liposomes, nanoparticles, proteinoid and amino acid microspheres, and pharmacosomes.

34. The dosage form of claim 33, wherein the vesicle is comprised of a nanoparticle.

35. The dosage form of claim 34, wherein the nanoparticle is a nanosphere, a nanocrystal, or a nanocapsule.

36. The dosage form of claim 1, wherein the active agent is enterically coated.

37. The dosage form of claim 36, wherein the active agent is water soluble but rendered sparingly water soluble by said vesicle.

38. The dosage form of claim 1, wherein the dosage form is comprised of a tablet.

39. The dosage form of claim 1, wherein the dosage form is comprised of a capsule.

52. A method for delaying the passage of a diuretic agent through the gastrointestinal tract of a patient, said method comprising orally administering the dosage form of claim 1 to the patient.

53. The method of claim 52, wherein the diuretic agent is selected from the group consisting of azetazolamide, amiloride, azosemide, bendroflumethiazide, bumetamide, chlorothiazide, chlorthalidone, ethacrynic acid, furosemide, hydrochlorothiazide, metolazone, muzolimine, nesiritide, piretamide, spironolactone, torsemide, triamterine, and tripamide.

54. The method of claim 53, wherein the diuretic agent is furosemide.

40. A gastric-retentive drug dosage form for delivering a pharmacologically active agent to the stomach, duodenum, and upper small intestine of a patient, the dosage form comprising a bilayer tablet having (a) a first layer that swells in the presence of water in gastric fluid such that the size of the dosage form is sufficiently increased to provide gastric retention in the stomach of a patient in whom the fed mode has been induced;

and (b) a second layer that contains the pharmacologically active agent and gradually erodes within the gastrointestinal tract over a determinable time period, wherein the bilayer tablet provides an active agent release profile in vivo that corresponds to a desired active agent release profile obtained for the dosage form in vitro using USP disintegration test equipment;

wherein the active agent is a diuretic agent.

41. A sustained release oral dosage form for delivering a pharmacologically active agent to the stomach, duodenum, and upper small intestine of a patient, the dosage form comprising a therapeutically effective amount of the pharmacologically active agent in a matrix of at least one biocompatible hydrophilic polymer, wherein the matrix delivers greater than about 80% of the active agent over a time period in the range of about 2 to about 8 hours in vitro as determined using USP disintegration test equipment, and further wherein the tablet is retained in the stomach when administered to a mammal in whom the fed mode has been induced;

wherein the active agent is a diuretic agent.

42. The dosage form of claim 41, wherein the matrix represents one layer of a bilayer tablet.

43. The dosage form of claim 42, wherein the bilayer tablet contains a second layer that swells in the presence of water or gastric fluid so that the size of the dosage form is sufficiently increased to provide gastric retention in the stomach of a mammal in whom the fed mode has been induced.

44. The dosage form of claim 41, wherein the diuretic agent is selected from the group consisting of azetazolamide, amiloride, azosemide, bendroflumethiazide, bumetamide, chlorothiazide, chlorthalidone, ethacrynic acid, furosemide, hydrochlorothiazide, metolazone, muzolimine, nesiritide, piretamide, spironolactone, torsemide, triamterine, and tripamide.

45. The dosage form of claim 44, wherein the diuretic agent is furosemide.

46. The dosage form of claim 43, wherein the in vivo disintegration time of the first layer is at least two hours shorter than the in vivo disintegration time of the second layer.

47. A method for selecting an optimized controlled release dosage form for administration to a patient such that the dosage form will have a predetermined drug release profile in vivo, the method comprising:

(a) preparing a plurality of different candidate dosage forms each comprised of a biocompatible, hydrophilic polymer and a pharmacologically active agent incorporated therein;

(b) obtaining the in vitro drug release profile for each candidate dosage form in an aqueous medium in a USP disintegration tester;

(c) comparing the in vitro drug release profiles obtained in (b), and determining which of the in vitro drug release profiles correlates most closely with a desired in vivo drug release profile; and

(d) selecting the dosage form having the determined in vitro drug release profile for administration to a patient;

wherein the pharmacologically active agent is a diuretic agent.

48. The method of claim 47, wherein the candidate dosage forms are all comprised of the same biocompatible, hydrophilic polymer but differ with respect to the amount or molecular weight thereof.

49. The method of claim 47, wherein the candidate dosage forms all contain the same pharmacologically active agent but differ with respect to the amount thereof.

50. The method of claim 47, wherein the diuretic agent is selected from the group consisting of azetazolamide, amiloride, azosemide, bendroflumethiazide, bumetamide, chlorothiazide, chlorthalidone, ethacrynic acid, furosemide, hydrochlorothiazide, metolazone, muzolimine, nesiritide, piretamide, spironolactone, torsemide, triamterine, and tripamide.

51. The method of claim 50, wherein the diuretic agent is furosemide.